THE US National Institute of Health halted trials using GlaxoSmithKline's AIDS drug Trizivir because it proved less effective than when used in combination with another treatment for the disease.
Create a FREE account to continue reading
Registration is a free and easy way to support our journalism.
Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.
Thank you for registering
Please refresh the page or navigate to another page on the site to be automatically logged in